GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Blood, American Society of Hematology, Vol. 112, No. 11 ( 2008-11-16), p. 3895-3895
    Abstract: The anti-tumor effect of donor lymphocyte infusions (DLI) after HLA-matched allogeneic stem cell transplantation (allo-SCT) can be mediated by donor T cells recognizing minor histocompatibility antigens (mHag) in the context of self HLA on the malignant cells of the recipient. However, T cells recognizing self antigens (Ag) that are overexpressed in malignant cells like the Wilms tumor protein (WT1) have also been proposed to contribute to the anti-tumor reactivity both after allo- and autologous SCT. WT1 is expressed in various types of cancer, including hematological malignancies at higher levels compared to their non-malignant counterparts. Different groups have isolated CD8+ HLA-A2 restricted WT1-specific T cells after HLA-matched transplantation and/or WT1 vaccination. Although these T cells stain with HLA-A2/WT1 peptide tetrameric complexes and are capable of recognizing peptide loaded HLA-A2+ target cells, recognition of primary leukemic cells could hardly be demonstrated. Stauss et al demonstrated recognition of endogenously processed Ag by WT1 specific T cells. However, these CD8 T cells were isolated in a situation where responder and stimulator cells were mismatched for HLA-A2. Based on these data we hypothesized that high avidity HLA-A2 restricted WT1 specific T cells may be deleted during thymic selection in HLA-A2+ donors. As a result, it is likely that only low avidity HLA-A2 restricted WT1 specific CD8+ T cells can be isolated from HLA-A2 positive donors, whereas it might be possible to isolate high avidity HLA-A2 restricted WT1 specific T cells from HLA-A2 negative donors due to the absence of the HLA restriction element in the thymus irrespective of the local WT1 expression. To test this hypothesis, we induced immune responses against the HLA-A2 binding WT1-derived peptide RMFPNAPYL using either HLA-A2+ or A2- donor T cells as responder cells. In case of HLA-A2+ donors (n=3) we stimulated CD45RO depleted donor T cells with autologous monocyte-derived antigen-presenting cells (APCs) loaded with 1E-6M WT1 peptide in the presence of 5ng/mL IL-7. At day 10 we either enriched tetramer-positive cells using immunomagnetic beads (MACS) or restimulated the responses with peptide-loaded autologous PBMC. At day 20 tetramer positive cells were isolated in bulk cultures and single cell/well by flowcytometric cell sorting. When using HLA-A2 negative donor T cells as responder cells, we used HLA-A2+ stimulator cells from an unrelated donor matched for all other class I alleles. The similar protocol was used for the induction of the immune response. At day 10 CD4+ T cells were depleted and the WT1 specific T cells were either enriched using tetramers and MACS or restimulated with peptide loaded HLA-A2+ PBMC. Using these approaches we were capable of isolating CD8+ T cell clones staining brightly with the A2/WT1 tetramer and expressing different T cell receptors (TCRs). HLA-A2+ WT1 specific T cells recognized only HLA-A2+ target cells loaded with 1E-8-1E-6M peptide both in IFNg release assays and cytotoxicity assays. Especially peptide-loaded target cells with an APC phenotype like EBVs were recognized efficiently, whereas normal peripheral blood cells were only recognized when loaded with 1E-6M peptide. In contrast, the HLA-A2 negative WT1-specific T cells efficiently recognized normal peripheral blood cells upon loading of 〈 1E-9M WT1 peptide, indicating that these T cells express TCRs with a higher affinity for the WT1 peptide compared to the HLA-A2+ WT1-specific T cells. Strikingly, EBV-LCL as well as TAP-deficient T2 cells were recognized by the HLA-A2 negative T cells even in the absence of exogenously loaded WT1 peptide. This might be due to the efficient recognition by the high avidity T cells of low levels of WT1 presented in HLA-A2 processed from the endogenous WT1 expression. However, due to the absence of HLA-A2 mediated thymic selection in HLA-A2 negative donors, cross-recognition of other peptides in HLA-A2 may also occur. In conclusion, high avidity WT1 specific CD8+ T cells could be exclusively isolated from HLA-A2 negative donor cells. These high avidity T cells are capable of recognizing target cells expressing very low levels of WT1. These T cell responses will gain more insight into the correlation of WT1 expression in different normal and malignant cell types and the recognition by high avidity WT1 T cells, and the clinical applicability of T cells directed against self antigens.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2008
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Journal of Immunotherapy, Ovid Technologies (Wolters Kluwer Health), Vol. 34, No. 3 ( 2011-04), p. 307-319
    Type of Medium: Online Resource
    ISSN: 1524-9557
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2011
    detail.hit.zdb_id: 2048797-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cytotherapy, Elsevier BV, Vol. 20, No. 4 ( 2018-04), p. 543-555
    Type of Medium: Online Resource
    ISSN: 1465-3249
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2018
    detail.hit.zdb_id: 2071176-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 114, No. 22 ( 2009-11-20), p. 4081-4081
    Abstract: Abstract 4081 Poster Board III-1016 T cells recognizing self antigens that are overexpressed in malignant cells such as the Wilms tumor protein (WT1) have been proposed to contribute to the anti-tumor reactivity after both allogeneic and autologous stem cell transplantation. The WT1 gene is expressed in human acute leukemia and chronic myeloid leukemia at much higher levels than in normal mononuclear blood cells and CD34+ hematopoietic progenitors. Various groups have attempted to use WT1 as a target in cancer immunotherapy. HLA-A2-restricted WT1-reactive CD8+ T cells that recognize peptide-loaded HLA-A2+ target cells have been isolated from both HLA-A2 negative and positive donors, but recognition of primary leukemic cells has only consistently been demonstrated with WT1-reactive CD8+ T cells generated in the mismatched setting. We hypothesized that HLA-A2-restricted WT1-specific CD8+ T cells generated from HLA-A2 positive donors are likely to be specific for the WT1 peptide, but may show only low reactivity against targets presenting endogenous WT1 antigen in the context of HLA-A2 due to thymic deletion of high affinity T cells. In contrast, HLA-A2-restricted WT1-specific T cells generated from HLA-A2 negative donors may be highly reactive against these targets, but with increased risk for cross reactivity. To test this hypothesis, WT1-specific T cells were generated from HLA-A2 positive and negative donors by stimulating purified CD8+ T cells with the HLA-A2 binding WT1126-134 peptide (RMFPNAPYL) loaded onto autologous dendritic cells in the case of HLA-A2 positive donors, or onto autologous HLA-A2 transduced EBV-LCL in the case of HLA-A2 negative donors. WT1-specific CD8+ T cell clones were isolated by flowcytometric cell sorting using WT1/A2 tetramers, and expanded. All T cell clones selected for functional analysis stained brightly with WT1/A2 tetramers, but not with irrelevant HLA-A2 control tetramers (PR1, PRAME, CMVpp65, HA-1), indicating specificity for the WT1 peptide presented in HLA-A2. Functional analysis was conducted using interferon-gamma (IFNg) ELISA and flowcytometric measurement of cytokine production and degranulation using HLA-A2+ EBV-LCL or T2 cells as target cells. WT1-reactive clones isolated from HLA-A2+ donors only recognized HLA-A2+ targets loaded with high ( 〉 10nM) concentrations of exogenous WT1 peptide, whereas most clones generated from HLA-A2 negative individuals showed high reactivity against the HLA-A2+ targets, even in the absence of exogenously loaded WT1 peptide, indicating cross-reactivity. To investigate antigen specificity, we constructed artificial antigen-presenting beads coated with HLA-A2 monomers containing different ratios of WT1 and CMVpp65 peptides, and used these beads to stimulate the WT1-reactive T cell clones. Dose dependent recognition of WT1, but not of the control pp65 peptide, was found for WT1 reactive T cell clones isolated from HLA-A2 positive donors as well as for clones from HLA-A2 negative donors. In response to stimulation with the various concentrations of WT1 loaded beads, IFNg production by WT1-reactive T cell clones from HLA-A2 negative donors was higher than production by clones from HLA-A2 positive donors, indicating that WT1-reactive clones from HLA-A2 negative donors had higher affinity for the HLA-A2/WT1 complex. To further examine and quantify the potential promiscuity of the WT1-reactive clones, we tested their capacity to bind a panel of 300 randomly selected HLA-A2 tetramers. Whereas clones generated from HLA-A2 positive individuals only recognized the WT1 tetramer, different WT1-reactive T cell clones generated from HLA-A2 negative individuals recognized approximately 5% of the tetramers, indicating that they were highly promiscuous in their peptide recognition. Competition experiments using HLA-A2+ target cells loaded with various concentrations of exogenous WT1 peptide indicated differential recognition of the HLA-A2 target peptides by different WT1-reactive T cell clones generated from HLA-A2 negative individuals. In conclusion, allogeneic HLA-A2-restricted WT1-specific T cells isolated from mismatched donors may be more tumor-reactive than their autologous counterparts, but show potentially hazardous promiscuity. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2009
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Immunology Research, American Association for Cancer Research (AACR), Vol. 7, No. 2_Supplement ( 2019-02-01), p. A044-A044
    Abstract: The most frequent subtype of acute myeloid leukemia (AML) is defined by mutations in the nucleophosmin (NPM1) gene. Mutated NPM1 is an attractive target for immunotherapy, since it is an essential driver gene and 4 base pair frameshift insertions in exon 12 occur in 30-35% of AML, resulting in a novel C-terminal alternative reading frame of 11 amino acids. By searching in the HLA class I ligandome of primary AML, we identified multiple peptides derived from mutated NPM1. For one of these peptides, i.e., HLA-A*02:01-presented CLAVEEVSL, we searched for specific T-cells in AML patients and healthy individuals using peptide-MHC tetramers. Tetramer-positive CD8 T-cell clones were isolated and analyzed for reactivity against primary AML with mutated NPM1. From one selected clone with superior antitumor reactivity, we isolated the T-cell receptor (TCR) and demonstrated specific recognition and lysis of HLA-A*02:01-positive AML with mutated NPM1 in vitro after retroviral transfer to CD8 and CD4 T-cells. In vivo antitumor efficacy of TCR-transduced CD8 and CD4 T-cells was confirmed in immunodeficient mice engrafted with a human AML cell line expressing mutated NPM1. These data show that mutated NPM1-derived peptides are presented on AML and that CLAVEEVSL is a neoantigen that can be efficiently targeted on AML with mutated NPM1 by TCR gene transfer in a co-receptor independent fashion. Immunotherapy targeting mutated NPM1 may therefore contribute to treatment of AML. Citation Format: Dyantha I. van der Lee, Rogier M. Reijmers, M. Willy Honders, Renate S. Hagedoorn, Rob. M. de Jong, Michel G.D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Christiaan Kweekel, Inge Jedema, Hendrik Veelken, Mirjam M. Heemskerk, Peter A. van Veelen, J.H. Frederik Falkenburg, Marieke Griffioen. Mutated NPM1 as target for immunotherapy of acute myeloid leukemia [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A044.
    Type of Medium: Online Resource
    ISSN: 2326-6066 , 2326-6074
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2019
    detail.hit.zdb_id: 2732517-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 106, No. 11 ( 2005-11-16), p. 3094-3094
    Abstract: Characterization of the antigens recognized by tumor-reactive T cells isolated from patients successfully treated with allogeneic HLA-matched stem cell transplantation (SCT) can lead to the identification of clinically relevant target molecules. We isolated cytotoxic CD8+ T cell (CTL) clones from a patient successfully treated with donor lymphocyte infusion for relapsed multiple myeloma (MM) after allogeneic HLA-matched SCT who suffered only from mild graft-versus-host disease (GVHD). The CTL clones were isolated by direct cloning of T cells producing IFN-γ upon stimulation with irradiated bone marrow cells harvested from the patient before SCT. The tumor-reactivity of the CTL clones was demonstrated by the recognition of MM cells in the bone marrow using the CFSE-based cytotoxicity assay. In addition to tumor cells, the CTL clones also lysed the patient-derived EBV-transformed lymphoblastoid cell line (EBV-LCL) and PHA-blasts, whereas donor-derived EBV-LCL cells and PHA blasts were not recognized demonstrating that these CTL clones were directed against a minor histocompatibility antigen (mHag). Using cDNA expression cloning, the target molecule of a HLA-B7-restricted CTL clone was identified. The CTL clone recognized a mHag produced by a non-synonymous single nucleotide polymorphism in the angiogenic endothelial cell growth factor-1 (ECGF-1) gene also known as thymidine phosphorylase. Analysis of the expression of the ECGF-1 gene in a micro array study demonstrated high levels of expression in hematopoietic cells, in particular CD14+ monocytes and DC, but ECGF-1 expression could also be detected in lung, liver and heart. We confirmed the expression pattern of ECGF-1 using quantitative real-time RT-PCR. CD14+ cells showed the highest levels of expression, although expression in other hematopoietic cells, like CD4+, CD8+ and CD19+ cells could also be detected. In agreement with the microarray study, expression of ECGF-1 in lung, liver and heart was found. By immunohistochemical analysis, it has been demonstrated that the expression of ECGF-1 in these tissues was mainly due to the presence of macrophages, although weak expression in stroma cells could also be detected. Although the patient from whom the CTL clone was isolated had more than 1% circulating ECGF-1-specific CD8+ T cells as determined with tetramer staining, she only suffered from mild GVHD indicating that the low level of ECGF-1 expression in some normal tissues has no major detrimental side effects. ECGF-1 is not only expressed in hematological tumors like multiple myeloma, CML and AML, but is also expressed in various other tumors, like melanoma, breast carcinoma and renal cell carcinoma. In these solid tumors, ECGF-1 can be expressed by the tumor cells themselves or by tumor-infiltrating monocytes. ECGF-1 expression is positively correlated with microvessel density and seems to be an unfavorable prognostic factor. The ECGF-1-specific CTL clone recognized mHag-positive, HLA-B7-expressing CML as well as melanoma cells, demonstrating that the ECGF-1-specific T cells are not only reactive against hematological malignancies but also against solid tumors. Therefore, ECGF-1 is an interesting target for immunotherapy of both hematological and solid tumors.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2005
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Journal of Clinical Investigation, American Society for Clinical Investigation, Vol. 129, No. 2 ( 2019-1-14), p. 774-785
    Type of Medium: Online Resource
    ISSN: 0021-9738 , 1558-8238
    Language: English
    Publisher: American Society for Clinical Investigation
    Publication Date: 2019
    detail.hit.zdb_id: 2018375-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...